Trials where anti‐CSF‐1R agents are combined with chemotherapy, immunotherapy, or targeted therapy are still ongoing, with only some very preliminary promising results (Peyraud et al, 2017), but fighting on several fronts could be the way forward in the treatment for aggressive tumors such as high‐grade gliomas. This evidence concerns the gene CSF1R and central nervous system cancer.